Description

This N-terminal tripeptide of IGF-I facilitated the in vitro release of acetylcholine with a several hundredfold higher potency (10-10 – 10-6 M) than intact IGF-I (4 ? 10-8 M), whereas truncated IGF-I lacking the tripeptide GPE, did not show any significant effect. This raises the possibility that GPE may be the active site of IGF-I. – Although the precise mode of action of GPE is still unknown, another study suggests that local administration of GPE is neuroprotective after brain HI injury via glial cells. In addition, systemic administration of GPE showed a more widespread neuroprotective effect. Therefore, GPE may represent a complementary pathway for central and systemic IGF-1’s antiapoptotic effects.

SEQUENCE: H-Gly-Pro-Glu-OH (trifluoroacetate salt)

ONE-LETTER SEQUENCE: GPE

MOLECULAR FORMULA: C₁₂H₁₉N₃O₆

MOLECULAR WEIGHT: 301.3

STORAGE CONDITIONS: -20 ± 5 °C

CAS REGISTRY NUMBER: [32302-76-4]

SYNONYMS:

RESEARCH AREA: Diabetes

REFERENCES:
L.Nilsson-Hakansson et al., NeuroReport, 4, 1111 (1993)
S.V.Sizonenko et al., Brain Res., 922, 42 (2001)
J.Guan et al., Neuropharmacology, 47, 892 (2004)
D.Aguado-Llera et al., Neuroreport, 15, 1978 (2004)
S.Shapira et al., Neurosci. Lett., 454, 53 (2009)

SKU(s): ILGF-003A

KEYWORDS: